ALK and non-small cell lung carcinoma: found that among the 275 patients with ALK+ NSCLC and BM who progressed after at least one line of systemic therapy, icORR, icDCR, and median time to progression of intracranial disease were 33%, 62%, and 12.3 months, respectively, for those previously treated with radiation, and 18%, 62% and 7 months, respectively, for those untreated (68).